When was Craif founded?

Craif was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Craif located?

Craif is headquartered in Tokyo, Japan.

Who is the current CEO of Craif?

Ryuichi Onose of Craif. They have also founded 1 company.

How many employees does Craif have?

As of May 31, 2026, the latest employee count at Craif is 53.

Is Craif a funded company?

Craif is a funded company, having raised a total of $39.7M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 15, 2019.

When was the latest funding round of Craif?

Craif's latest funding was a $***** Series C round on Apr 28, 2025, with participation from 8 investors.

Where does Craif rank among its competitors?

Craif ranks 55th amongst 729 active competitors, of which 221 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Guardant Health, which secured $350M in Nov, 2025.

Who are the top competitors of Craif?

Craif's top competitors include Guardant Health, Natera and Myriad Genetics. Among them, Guardant Health secured the most recent funding round in November, 2025.

Craif - 2026 Company Profile, Team, Funding & Competitors

Craif is a series C company based in Tokyo (Japan), founded in 2018 by Ryuichi Onose and Takao Yasui. It operates as a Developer of a device for cancer detection. Craif has raised $39.7M in funding from investors like ANRI, JST and Mori Trust. The company has 729 active competitors, including 221 funded and 171 that have exited. Its top competitors include companies like Guardant Health, Natera and Myriad Genetics.

Company Details

Developer of a device for cancer detection. The company has developed a novel device that is used to collect and separate the microRNA secreted from cancer cells present in the urine. The device uses a combination of zinc oxide nanostructures and microflow channel technologies for the process and early cancer detection.

Key Metrics

Founded Year

2018

Location

Tokyo, Japan

Stage

Series C

Total Funding

$39.7M in 7 rounds

Latest Funding Round

Series C, Apr 28, 2025, $*****

Investors

ANRI & 19 more

Ranked

55^th among 729 active competitors

Employee Count

53 as on May 31, 2026

Similar Companies

Guardant Health & 981 more

View Craif's full profile

Craif has raised a total funding of $39.7M over 7 rounds. Its first funding round was on Feb 15, 2019. Its latest funding round was a Series C round on Apr 28, 2025 for $*****. 8 investors participated in its latest round. Craif has 20 institutional investors.

Here is the list of recent funding rounds of Craif:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 28, 2025	1904516	Series C	6561433	9730660	3096541	1667958
Dec 23, 2024	3516209	Series C	7644457	6362837	4412217	X&
Mar 04, 2024	5667448	Series B	5958291	2992606	Toyoda Gosei	6120579

Access funding benchmarks and valuations. Sign up today!

View details of Craif's funding rounds and investors

The founders of Craif are Ryuichi Onose and Takao Yasui. Ryuichi Onose is the CEO of Craif.

Here are the details of Craif's key team members:

Ryuichi Onose: Co-Founder & CEO of Craif and founder of 1 other company.
Contact Info: 2 email addresses
Takao Yasui: Co-Founder of Craif and founder of 1 other company.
Contact Info: 1 email address

View details of Craif's Founder profiles and Board Members

Craif's employee count trend

Craif has 53 employees as of May 26. Here is Craif's employee count trend over the years:

Uncover Craif's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Craif include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of Craif, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Orbimed, Sequoia Capital & 25 others	79/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Harmony Venture Partners ... & 17 others	77/100
3rd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	72/100
4th	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Baillie Gifford, Bezos Expeditions & 10 others	72/100
5th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Deerfield, Casdin Capital & 11 others	71/100
6th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	71/100
7th	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	71/100
8th	Personalis 2011, Menlo Park (United States), Public	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	70/100
9th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Beyond Ventures, Ping An Ventures & 21 others	70/100
10th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 29 others	69/100
55th	Craif 2018, Tokyo (Japan), Series C	Developer of a device for cancer detection	$39.7M	Mori Trust, Global Brain & 18 others	56/100